Uncategorized

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder

Relmada Therapeutics, Inc. today announced the dosing of the first patient in the Relight (study 304) Phase 3, randomized, double-blind, placebo-controlled trial evaluating REL-1017 as an adjunctive treatment of Major Depressive Disorder (MDD).

Relmada Therapeutics Announces Dosing of First Patient in Relight, a Phase 3 Trial of REL-1017 for the Adjunctive Treatment of Major Depressive Disorder Read More »

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Pfizer Inc. and Astellas Pharma Inc. announced that the U.S. Food and Drug Administration has accepted and granted Priority Review for the companies’ supplemental New Drug Application for XTANDI® for the treatment of patients with non-metastatic castration-sensitive prostate cancer with high-risk biochemical recurrence.

FDA Grants Priority Review for XTANDI® in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence Read More »

Scroll to Top